24/7 Patient Assistance: 760-405-8205

Jan Buckner, MD

Medical Oncologist

Write a review
Doctor's profile photo

Request a call back

Conditions Treated Asbestosis Laryngeal Cancer Lung Cancer Pericardial Mesothelioma Pleural Mesothelioma

Hospitals & Clinics

specialties & services

  • Bio & Insurance Information

    Dr. Jan Buckner is a medical oncologist in Rochester, Minnesota. He got his medical degree from University of North Carolina at Chapel Hill School of Medicine and did his residency at Spectrum Health-Butterworth Campus. Dr. Buckner went to Mayo School of Graduate Medical Education and obtained his fellowship in medical oncology. He is certified by the American board in both medical oncology and internal medicine. Dr. Buckner has over 20 years of experience and is currently affiliated with Mayo Clinic – Rochester.

  • Education & Training


    University of North Carolina at Chapel Hill School of Medicine

    Medical School


    Spectrum Health-Butterworth Campus



    Mayo School of Graduate Medical Education


  • Board Certifications

    American Board of Internal Medicine

    American Board of Internal Medicine - Oncology

  • Hospital & Practice

    Mayo Clinic Rochester

    Languages: English/Spanish


    200 S. W. First Street

    Rochester, Minnesota 55905

    Read More
  • Publications & Memberships

    Dr. Jan Buckner has contributed to 5 publications.

    MRI texture features as biomarkers to predict MGMT methylation status in glioblastomas.

    Korfiatis, P.,Kline, T. L.,Coufalova, L.,Lachance, D. H.,Parney, I. F.,Carter, R. E.,Buckner, J. C.,Erickson, B. J.; Med Phys.

    See more >>

    Pragmatic study designs for older adults with cancer: Report from the U13 conference.

    Nipp, R. D.,Yao, N. A.,Lowenstein, L. M.,Buckner, J. C.,Parker, I. R.,Gajra, A.,Morrison, V. A.,Dale, W.,Ballman, K. V.; J Geriatr Oncol.

    See more >>

    Adult patients with supratentorial pilocytic astrocytoma: long-term follow-up of prospective multicenter clinical trial NCCTG-867251 (Alliance).

    Brown, P. D.,Anderson, S. K.,Carrero, X. W.,O\'Neill, B. P.,Giannini, C.,Galanis, E.,Shah, S. A.,Abrams, R. A.

    See more >>

    Quantification of the impact of enzyme-inducing antiepileptic drugs on irinotecan pharmacokinetics and SN-38 exposure.

    Berg, A. K.,Buckner, J. C.,Galanis, E.,Jaeckle, K. A.,Ames, M. M.,Reid, J. M.; J Clin Pharmacol

    See more >>

    A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma:

    NCCTG N057K. Ma, D. J.,Galanis, E.,Anderson, S. K.,Schiff, D.,Kaufmann, T. J.,Peller, P. J.,Giannini, C.,Brown, P. D.,Uhm, J. H.,McGraw, S.,Jaeck

    See more >>


    American Society of Clinical Oncology